Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Escalating Oral Doses of LY2393910 in Patients With Type 2 Diabetes Mellitus.
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2011
At a glance
- Drugs LY 2393910 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 09 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Apr 2011 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.